Cover Image
市場調查報告書

惡病質:主要8市場預測

Cachexia Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 370681
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
惡病質:主要8市場預測 Cachexia Forecast in 8 Major Markets 2016-2026
出版日期: 2016年09月16日 內容資訊: 英文 46 Pages
簡介

本報告提供主要8個市場 (美國、法國、德國、義大利、西班牙、英國、巴西以及日本) 的惡病質的目前患者數 (性別、各年齡世代) 調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

患者數的定量化方法

惡病質的最大患病人數

惡病質患者的特徵

  • 惡病質:患者的病因論
  • 伴隨惡病質:的COPD患者
  • 伴隨惡病質:的CKD患者
  • 伴隨惡病質:的CHF患者
  • 伴隨惡病質:的癌症患者

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

線上價格資料、平台

參考文獻

附錄

目錄
Product Code: CCHX0010916

image1

According to the most recent consensus statement (Muscaritoli et al 2010), cachexia can be defined as weight loss exceeding 5% within the previous 3-12 months in patients with long term chronic conditions OR BMI < 20 kg/m2, combined with symptoms characteristic for cachexia, loss of skeletal muscle and biochemical abnormalities. While the same mechanisms that contribute to sarcopenia undoubtedly contribute to cachexia, in addition there are specific mechanisms that contribute to muscle wasting from an underlying pathology. These include: inflammation, in particular IL-6, IL-1 and TNF-α, and irregular protein metabolism. Patients with cachexia tend to burn more energy during their resting state than sarcopenic patients.

This report provides the current prevalent population Cachexia across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Cachexia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key underlying pathologies linked with developing cachexia include:

  • COPD
  • CKD and end stage renal disease (ESRD)
  • CHF
  • Cancer
  • AIDS and HIV
  • Rheumatoid arthritis and other autoimmune conditions

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in the global Cachexia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Cachexia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Cachexia's prevalent population.
  • Identify sub-populations within Cachexia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Cachexia patients.

Coverage

BR, FR, DE, IT, JP, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Cachexia

Features of Cachexia Patients

  • Aetiology of Cachexia Patients
  • COPD Patients with Cachexia
  • CKD Patients with Cachexia
  • CHF Patients with Cachexia
  • Cancer Patients with Cachexia

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Figures

  • Stages of cancer cachexia
  • Conceptual representation of the definition of cachexia

List of Tables

  • Difference between sarcopenia and cachexia
  • Leading cause of cachexia
  • Prevalence of Cachexia, total (000s)
  • Prevalence of Cachexia, , males (000s)
  • Prevalence of Cachexia, , females (000s)
  • Cachexia patients by aetiology, total (000s)
  • COPD Cachexia patients by GOLD stage. total (000s)
  • CKD Cachexia patients by CKD stage. total (000s)
  • CHF Cachexia patients by Ejection fraction HF type, total (000s)
  • Cancer Cachexia patients by cancer type, total (000s)
  • Digestive cancer Cachexic patients by cancer type, total (000s)
  • Haematological cancer Cachexic patients by cancer type, total (000s)
  • Head & Neck cancer cachexic patients by cancer type, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • USA Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • France Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • France Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Germany Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Germany Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Italy Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Italy Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Spain Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Spain Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Cachexia by 5-yr age cohort, females (000s)
  • Japan Prevalence of Cachexia by 5-yr age cohort, males (000s)
  • Japan Prevalence of Cachexia by 5-yr age cohort, females (000s)
Back to Top